**Name of journal: *World Journal of Gastrointestinal Endoscopy***

**Manuscript NO: 33101**

**Manuscript type: Minireviews**

**Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease**

Shukla R *et al*. Chromoendoscopy for dysplasia surveillance in IBD

**Richa Shukla, Mark Salem, Jason K Hou**

**Richa Shukla, Mark Salem, Jason K Hou,** Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, United States

**Jason K Hou,** Houston VA HSR&D Center of Excellence, Michael E. DeBakey VAMC, Houston, TX 77030, United States

**Author contributions:** Shukla R contributed in the literature review and primary authorship of the manuscript; Salem M and Hou JK contributed in literature review and editorial input in the manuscript; all authors approved of the final draft submitted.

**Conflict-of-interest statement:** Hou JK has received research funding from Redhill Biosciences, Coronado Biosciences, Celgene, Pfizer Inc. JH serves on the speaker bureau for Abbvie, Janssen, and UCB pharmaceuticals.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Jason K Hou, MD, MS,** Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine,One Baylor Plaza, BCM901, Houston, TX 77030, United States. jkhou@bcm.edu

**Telephone:** +1-713-7980950

**Fax:** +1-713-7980951

**Received:** January 28, 2017

**Peer-review started:** February 9, 2017

**First decision:** march 22, 2017

**Revised:** April 13, 2017

**Accepted:** July 7, 2017

**Article in press:**

**Published online:**

**Abstract**

Traditionally, patients with inflammatory bowel disease (IBD) have been thought to be at increased risk of developing colitis-associated colorectal cancer. Although there are recent data suggesting that rates of colitis-associated cancer in IBD patients is declining, current guidelines still recommend regular dysplasia surveillance for early detection and prevention of neoplasia in patients with IBD. White-light endoscopy with random biopsies has been the traditional approach for dysplasia detection; however, newer technologies and approaches have emerged. One method, dye-based chromoendoscopy, has the potential to detect more dysplasia. However, longitudinal data to showing a benefit in morbidity or mortality from the use of chromoendoscopy are still lacking. Many societies have included recommendation on the use of chromoendoscopy with targeted biopsies as a method of surveillance for colitis- associated colorectal cancer. This narrative review seeks to outline data on dysplasia detection as well as barriers to the implementation of dye-based chromoendoscopy for the prevention and early detection of colitis-associated colorectal cancer.

**Key words:** Inflammatory bowel disease; chromoendoscopy; dysplasia surveillance

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Patients with inflammatory bowel disease (IBD) are at an increased risk of developing colorectal cancer. Current guidelines recommend surveillance for early of neoplasia in patients with IBD. White-light endoscopy with random biopsies has been the traditional approach for dysplasia detection. Dye-based chromoendoscopy has the potential to detect more dysplasia. Many societies have endorsed the use of chromoendoscopy with targeted biopsies as a method of surveillance for colitis associated colorectal cancer. This review seeks to outline data on dysplasia detection as well as barriers to the implementation of chromoendoscopy for the prevention and early detection of colitis associated colorectal cancer.

Shukla R, Salem M, Hou JK. Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease. *World J Gastrointest Endosc* 2017; In press

**Introduction**

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory disease of the GI tract. Both ulcerative colitis and Crohn’s colitis have historically been thought to be associated with an increased risk of developing colorectal cancer (CRC)[1-3]. Current guidelines provide various permutations of surveillance colonoscopy to detect and remove precursor lesions at an early stage[4-7]. Over the last several years, dye-based chromoendoscopy (CE) with targeted biopsies has emerged as an option to improve the ability to detect these early, subtle lesions. CE is a technique using absorptive stains or contrast stains dye such as methylene blue and indigo carmine that can aid in the early detection of malignant changes in the gastrointestinal tract. In this technique, 0.4% indigo carmine or 0.1% methylene blue is sprayed directly onto the colonic mucosa to help detect subtle mucosal irregularities that aid in the detection of changes indicative of dysplasia as well as help in differentiation of neoplastic and non-neoplastic lesions by assessing crypt architecture and modified pit patterns[8]. The technique of colonic CE was first described by Tada in 1976 with work two decades later indicating a role for CE with high resolution video endoscopy in increasing the detection of small flat neoplastic lesions in UC patients[9,10]. In this review, we will review current guidelines for the surveillance of colitis-associated colorectal cancer (CAC), barriers to implementation, and areas that require further study.

**Colorectal cancer risk among patients with IBD**

The concept of carcinoma arising as a complication of chronic inflammation from IBD was first described by Crohn and Rosenberg in 1925, with later reports expanding on this observation[1-3]. A review of the literature in 1961 by Goldgraber and Kirsner made the observation of increased risk of carcinoma of the colon in patients with UC with pancolonic disease and in those with disease duration greater than 10 years[2]. The presence of dysplastic lesions in the colon of patients with UC was recognized as early as 1949 with the recommendation to search for precancerous lesions which often were flat (non-polypoid) with rectal biopsies annually as an aid to the detection of early colon cancer being made in 1969[11,12]. It was not until 1983 that a standardized terminology and grading system were established to help guide surveillance protocols. In the landmark paper by Riddell in 1983, dysplasia was defined as an unequivocal neoplastic alteration of the colonic epithelium that may represent a precursor of carcinoma or itself be malignant and associated with direct invasion into the underlying tissue. The classification for dysplasia was further categorized into either negative, indefinite or positive for dysplasia[13].

In a landmark meta-analysis conducted by Eaden *et al*[14] in 2001, the authors assessed 116 studies and found that the cumulative risk of developing CAC was 2% by 10 years of disease, 8% by 20 years, and 18% by 30 years. Subsequent studies investigating the CAC risk in IBD patients have shown considerable variability, depending on the population studied, with cumulative risk ranging between 2.1% to 33.2%[15-18] Remarkably, more recentstudies have actually shown that the risk of CAC in IBD patients may actually be declining and nearing the risk of the general population[19]. In a meta-analysis by Jess *et al*[20] assessing 47374 Danish patients with IBD over 30 years, the authors found that the relative risk of developing CAC in UC patients was comparable to non-IBD controls (RR = 1.07, 95%CI: 0.95-1.21) as was the risk of CAC in patients with Crohn’s colitis (RR = 0.80; 95%CI: 0.43-1.49). This study also found that the overall risk of CAC was declining in UC patients where the overall RR for CAC decreased from 1.34 (95%CI: 1.13-1.58) in 1979–1988 to 0.57 (95%CI: 0.41-0.80) in 1999-2008. This decline potentially may be attributed to improvement in therapies to reduce intestinal inflammation in IBD or to improved surveillance programs to promote early detection of neoplastic lesions.

Despite the decline in overall risk, there is still consistent information across many studies that there is a particularly higher risk of developing CAC in a subset of patients – those with extensive and long standing UC or CD[20-22]. Rutter *et al*[23] evaluated 68 patients in a case-control study at St. Mark’s Hospital in England and found that severity of colonic inflammation is also an important predictor for development of neoplasia. Moreover, in the aforementioned study by Jess *et al*[20], despite an overall decline in incidence of CAC in IBD patients, there are particular subsets of patients- those with a diagnosis of UC in childhood or adolescence, those with long standing UC and those with concurrent primary sclerosing cholangitis (PSC)- who were at a notably increased risk of developing CAC during the study period.

**Current Guidelines for CAC Surveillance**

While CAC may only represent a small proportion of all CRC cases (1%-2%), colorectal cancer is responsible for one in six deaths of IBD patients[24]. As such, colonoscopy has been the test of choice for early detection and prevention of CAC in IBD patients. The major United States gastroenterology societies have endorsed colonoscopy for prevention of early CAC[25-27]. There are limited data on the benefit of the recommended surveillance programs. Some studies have found that patients with IBD undergoing surveillance colonoscopies may have reduced rates of CAC or detection of CAC at an earlier stage[28].

Choi *et al*[29] examined 41 UC patients who developed CAC. The authors found that CAC was detected at a significantly earlier Dukes' stage in patients taking part in an endoscopic surveillance program (*P* = 0.039). Furthermore, the 5-year survival rate was 77.2% for the surveillance group and 36.3% for the no-surveillance group (*P* = 0.026). Though this study is promising evidence in favor of CRC surveillance, other studies have not shown a similar benefit. Lynch *et al*[30] prospectively examined 160 UC patients and found no mortality benefit in patients undergoing CRC surveillance.More recently, Ananthakrishnan *et al*[31] studied 6823 established patients (following for at least 3 years) with IBD of which 2764 had undergone recent colonoscopy. They found that the incidence of CAC among patients without a recent colonoscopy (2.7%) was significantly higher than among patients with a recent colonoscopy (1.6%) (OR = 0.56, 95%CI: 0.39-0.80). This was one of the few studies which specifically addressed the risk of CAC in IBD patients undergoing surveillance.

Current society guidelines recommend regular dysplasia surveillance in patients with long-standing colitis. Several major GI societies guidelines, including those published by the American Gastroenterological Association in 2003, recommend initiating a surveillance program to evaluate for dysplasia in patients who have had colitis for at least 8 years[4,5]. After starting a surveillance program, colonoscopy should continue every 1-2 years. The consensus of the expert panel formulating these guidelines is that random biopsy specimens should be taken every 10 cm in all 4 quadrants and that additional biopsies should be taken of any endoscopically abnormal appearing lesions (strictures, mass lesions, *etc*). This results in a minimum of 33 biopsies to meet the threshold for neoplasia detection - a process that can be quite cumbersome and time consuming. Newer society guidelines, such as those issued by the American Society for Gastrointestinal Endoscopy (ASGE) and the European Crohn’s and Colitis Organization (ECCO)[6,7], have now updated their guidelines to incorporate the use of chromoendoscopy for dysplasia surveillance. A summary of the current guidelines from the major GI societies is outlined in Table 1.

There have been many criticisms of the random biopsy strategy as less than 1% of the entire mucosal surface was sampled and low dysplasia detection rates as well as high sampling-error[32]. There are also no prospective studies that have determined the optimal number of biopsies that should be taken to detect dysplasia reliably though one study has recommended a minimum of 33 biopsy specimens to be taken in patients with pancolitis[33]. It has also been estimated that this surveillance method provides only 80% confidence that dysplasia involving ≥ 5% of the colon can be detected[34]. There have also been several studies showing poor adherence of gastroenterologists in taking the recommended number of biopsies along with practice variability in surveillance[35-37]. These initial recommendations were made at time prior to high-definition colonoscopy and lesions previously considered “invisible” or flat may be visualized with modern day high-definition equipment. It is now understood that most dysplasia can be visualized endoscopically and have led some to question the added value of random biopsies[26]. Recent studies have supported the strategy of targeted biopsies of abnormal lesions without random biopsies only when high definition white light endoscopy (HD-WLE) is used. A clinical practice cohort of 454 IBD patients undergoing surveillance colonoscopy between 2011-2014 using standard definition white light endoscopy (SD-WLE), HD-WLE, virtual electronic CE, or CE found that most lesions were visible and of the four dysplastic lesions and one adenocarcinoma identified all were visible with HD-WLE and biopsied in a targeted manner. No dysplasia was identified on random biopsies[38]. A recent randomized controlled trial of 256 of patients with UC performed in Japan comparing surveillance with either a targeted biopsy protocol *vs* a random biopsy protocol with white light endoscopy found neoplasia was detected in 11.4% of patients in the targeted biopsy group *vs* 9.3% in the random biopsy group (*P* = 0.617) with less biopsies specimens being required per neoplasia diagnosis, suggesting a targeted biopsy approach as being more cost-effective and more efficient without missing dysplasia[39].

**SCENIC Consensus Statement**

In March of 2015, the SCENIC (Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients: International Consensus Recommendations) consensus statement[40] regarding use of chromoendoscopy for dysplasia surveillance was released. In this statement, the authors made several updates regarding the approach to dysplasia surveillance among which they suggested that endoscopists consider the use of CE, when utilizing high definition colonoscopy, to enhance dysplasia detection. A commentary by Marion and Sands[41] accompanying the publication of the SCENIC statement propounded an important argument: the lack of longitudinal data regarding CE limits the ability to accept this as the standard of care in dysplasia surveillance. More specifically, while there is certainly evidence that CE increases dysplasia detection, it remains unclear what the long-term management of these patients should be. While pursuing the goal of cancer prevention, the accompanying risk profile of increased dysplasia detection including onerous surveillance schedules, possibly unnecessary colectomies or post-surgical complications also increases. This risk/benefit profile, along with the limited evidence to support use of CE, must all be considered when deciding to employ this technique.

**Evidence for Chromoendoscopy**

Two studies increased the attention on CE as a means to more efficiently detect dysplasia in IBD compared to random biopsies. In one study of 100 patients with long-standing UC using a tandem colonoscopy design, random biopsies along with targeted biopsies using standard white light was compared to CE with targeted biopsies only using indigo carmine. This study demonstrated a 3.5-fold increase in diagnostic yield of dysplasia along with a 4.5-fold increase in dysplasia detection, with no dysplasia being detected on random biopsies[42]. In the first randomized prospective trial using CE for IBD-associated colonic dysplasia, methylene blue was compared to conventional colonoscopy in patients with long-standing UC. Chromoendoscopy was associated with an increased diagnostic yield for total number of detected intraepithelial neoplasia compared to conventional colonoscopy (32 *vs* 10, *P* = 0.003) The CE group also required less biopsies and using the modified pit pattern demonstrated a sensitivity and specificity for differentiation between neoplastic and non-neoplastic lesions of 93%[43]. Subsequent studies also have shown an increased detection yield of CE over standard white light endoscopy (WLE), which was highlighted by a meta-analysis evaluating prospective studies comparing CE to WLE. Six prospective studies were included in the analysis and concluded that CE resulted in a 7% higher yield in detection of neoplasia as well as a pooled increase in targeted dysplastic (low or high grade) lesion detection of CE over standard definition WLE of 44% (95%CI: 28.6-59.1)[44]. Mounting data of the effectiveness in dysplasia detection with CE lead to the 2010 position statement from the American Gastroenterological Association (AGA) recommending CE as an alternative to analyses of random biopsies for endoscopists experienced with the technique[45]. The British Society of Gastroenterology (BSG) also recommended CE with targeted biopsies with a grade A recommendation as the preferred method of surveillance [46].

Though clinical trials demonstrated a benefit of CE over WLE for dysplasia detection, a large retrospective study covering 13 years did not confirm this conclusion in the clinical practice setting. This multicenter study from the Netherlands including 401 patients undergoing CE and 772 patients undergoing WLE found no difference in the detection of dysplasia between the two groups (11% *vs* 10%, *P* = 0.80)[47]. This conclusion was in accordance with a previous study using narrow-band imaging showing no difference in dysplasia yield between CE and HD WLE[48]. Of note, the authors of this study highlighted that prior studies assessing outcomes in chromoendoscopy had a “back-to-back” design where WLE was performed first followed by CE (as WLE cannot be performed after dye spraying). They postulated that such a design may have overestimated the yield of CE in detecting neoplasia and generated potential bias. To try and fill the discrepancy in the data, Carballal *et al*[49] conducted the first randomized prospective trial evaluating the real-life experience of CE for dysplasia detection in long-standing IBD. In this prospective, multicenter cohort study from Spain, 350 patients with long-standing IBD underwent surveillance using a tandem colonoscopy method with each colonic segment being evaluated with WLE followed by CE using 0.4% indigo carmine with targeted biopsies of suspicious lesions. This study found a 57.4% incremental yield in dysplasia detection with CE versus WLE which was comparable in standard WLE vs HD WLE. The dysplasia miss rate was 40 of 94 lesions for white-light examination. Overall dysplasia detection rate was 15.7% in this real-life setting which is in line with previous estimates[50]. This study also demonstrated no significant difference in dysplasia detection between CE-expert and non-expert endoscopists with no significant learning curve being observed. Though it has been concluded that CE improves dysplasia detection and is the most effective modality for surveillance, data regarding the effect on patient outcomes and cancer-related morbidity and mortality are still lacking.

**Barriers to Performing Chromoendoscopy**

While CE may provide some benefit with regards to increased dysplasia detection, there are several barriers to performing CE that must be considered when deciding whether to implement this technique.

***Does expertise affect outcomes?***

Much of the existing data, especially data demonstrating positive results, on CE arises from centers where gastroenterologists have particular expertise in performing CE[42,43,50-53]. In the article by Mooiweer *et al*[47], the neoplasia detection rate for CE-based surveillance procedures was 11% compared with an average rate of 14% over several prior randomized trials examining neoplasia detection using CE. The authors of the study postulated that the lower neoplasia detection rate could be due to the inexperience of the endoscopists who had no dedicated training prior to performing the CE procedures. Conversely, Carrabal *et al*[49] prospectively examined a cohort of IBD patients undergoing dysplasia surveillance between 2012-2014. The study protocol required that each colonic segment was evaluated with white light followed by 0.4% indigo carmine CE. When assessing for differences between expert (endoscopists who had performed > 20 CE-based dysplasia surveillance procedures) and non-expert endoscopists, the dysplasia detection rate was not found to be significantly different between the two groups (18.5% *vs* 13.1%, *P* = 0.20).

***Cost concerns and technical disadvantages associated with CE***

The equipment required to perform chromoendoscopy usually includes one of the absorptive, contrast or reactive stains; these stains are generally inexpensive but have had issues with availability at times. Additionally, when performing chromoendoscopy, a spray catheter may be used to apply a uniform mist of the staining agent. The cost of these spray catheters is between approximately $50-200.The equipment used to perform chromoendoscopy is compatible with most commonly used colonoscopies and the staining dyes are thought to add no additional risk to the patient[54].While the equipment may only add a small amount of cost to the procedure, the cost of additional time to perform high quality chromoendoscopy harder to quantify. The data on cost-effectiveness of this technique is quite limited. One formal cost effectiveness study has been conducted by Konijeti *et al*[55]. The authors utilized a Markov model to analyze the cost effectiveness of CE relative to WLE or no endoscopy for CRC surveillance in UC patients. This study design was chosen to better analyze need for surveillance and optimal surveillance intervals given increasing data about decreasing rates of CRC in patients with IBD. CE was found to be more effective and less costly than WLE at all surveillance intervals. However, compared with no surveillance, CE was cost effective only at surveillance intervals of at least 7 years, with an incremental cost-effectiveness ratio of $77176. While this study suggests that CE may be more cost effective than white-light endoscopy, it only demonstrates a cost benefit over no surveillance if intervals are stretched out to greater than every 7 years. Overall, the question on whether chromoendoscopy offers a cost savings when used in a real-world surveillance program remains unanswered and more studies are required to truly clarify this.

One additional barrier that may prevent gastroenterologists in implementing CE is the additional procedure time. In the meta-analysis conducted by Subramanian *et al*[44], taking data from experienced centers, CE increased procedure time by 11 min overall. In the previously mentioned study by Kiesslich *et al*[43], procedure time was increased from 35 to 44 min (with CE) overall. However, this procedure time also included time dedicated for random biopsies. If a practice of conducting only targeted biopsies of suspicious lesion were employed, the additional procedure time added by using CE would likely be less. Additionally, increasing experience with CE may translate into shorter procedure times. In an implementation study by Leong *et al*[56], the authors observed that withdrawal time decreased with experience, ranging from 31 min for fewer than 5 procedures to 19 min for more than 15 procedures completed.

**Clinical Impact of Chromoendoscopy**

CE is highlighted as a more effective modality than high definition white light endoscopy for detecting “invisible dysplasia”. However, it is important to consider whether there is truly a significant clinical impact of missed, “invisible” dysplastic lesions on CAC-related outcomes. To answer this question, Rubin *et al*[25] conducted a retrospective review of all cases of dysplasia or CRC in UC between November 1994 and October 2004. There were 1339 surveillance examinations in 622 patients with UC; forty-six patients were found to have dysplasia or CRC. 75 separate dysplastic or cancerous lesions were identified, 38 of 65 dysplastic lesions (58.5%) and 8 of 10 cancers (80.0%) were visible to the endoscopist as 23 polyps and masses, 1 stricture, and 22 irregular mucosa. Moreover, van den Broek *et al*[57] conducted a retrospective analysis of 1010 colonoscopies from 1998-2008. In total, 475 patients with UC were included in the study. Of all colonoscopies, 466 were performed for surveillance (in 167 patients) during which 11772 random biopsies were taken (median 29). Dysplasia was detected in random biopsy specimens alone in 5 colonoscopies (0.5%) in 4 patients

(0.8%). Of these 4 patients, 2 had had visible dysplasia in previous colonoscopies, 1 had unifocal low-grade dysplasia that was not confirmed in 3 subsequent colonoscopies, and 1 had multifocal low-grade dysplasia and suspicious appearing ulcerations and underwent proctocolectomy, which confirmed the presence of neoplasia. Thus, dysplasia uncovered via random biopsy changed the management of only 1 of 475 patients (0.2%). In comparison, targeted biopsy specimens were positive for neoplasia in 83 colonoscopies (8.2%), and major therapeutic decisions (endoscopic resection or colectomy) were made in 61 of these cases (73%). This data suggests that “invisible dysplasia” detected on random biopsy is infrequent and of unclear clinical relevance. Though recent published data has shown promising results for a targeted biopsy approach to dysplasia surveillance[38], the issue of invisible dysplasia likely remains an open issue that requires future investigation before eliminating random biopsy protocols altogether.

***Does dysplasia detection affect long-term outcomes?***

In a meta-analysis by Subramanian *et al*[44], the authors assessed the diagnostic yield, for detection of dysplasia between white light endoscopy and CE. In 6 studies involving 1277 patients, the difference in yield of dysplasia between CE and white light endoscopy was 7% (95%CI: 3.2-11.3) with a number needed to treat of 14.3. The difference in proportion of lesions detected by targeted biopsies was 44% (95%CI: 28.6-59.1) and flat lesions was 27% (95%CI: 11.2-41.9) in favor of CE. The aforementioned prospective studies, derived from expert centers, have demonstrated a significant difference in dysplasia detection with the utilization of CE[42,43,50-53]. It must be noted, however, that most of these studies follow a cross-sectional design in which the number of detected lesions using CE is compared with the number of lesions detected using standard definition white-light endoscopy.

The intended goal of surveillance strategies is to detect early lesions that would lead to decreased colon cancer morbidity and mortality as well as unnecessary colectomies. Although chromoendoscopy may help to increase dysplasia detection compared to white light endoscopy, the clinical implications of this increased detection yield are largely unknown. In a follow-up[58] to an initial Index Study[50] looking at 102 high-risk IBD patients undergoing surveillance comparing CE and SD-WLE with random biopsy, 68 patients were longitudinally followed over a median of 27.8 months to compare the techniques for dysplasia detection. CE was found to be more likely to detect dysplasia compared to targeted WLE (OR = 2.4, 95%CI: 1.4-4.0) and random biopsy (OR = 5.4, 95%CI: 2.9-9.9) Furthermore, in the 10 patients who underwent colectomy, CE was found to have better overall agreement between endoscopy and colectomy findings regarding the presence or absence of dysplasia which was 80% in CE, 20% for random biopsy and 10% in targeted WLE. Furthermore, a negative result from CE was the best indicator of dysplasia free outcome which may play a role in future decisions regarding recommended screening intervals. There is recent data with conflicting results regarding the impact of lesions detected with CE compared to WLE. In a retrospective study evaluating the implications of LGD found during surveillance in a Dutch cohort, 159/1065 patients evaluated were found to have LGD (133 visible lesions and 26 invisible lesions) for an overall incidence rate of 1.34 per 100 patient-years for all LGD lesions. There was a total of 10 cases which advanced to either HGD (5/10) or CRC (5/10) with no significant difference in the risk of advanced neoplasia during follow-up for index lesions detected with either WLE or CE[59]. Though there was no difference in advancement in lesions detected by HD-WLE *vs* CE, this may have been limited by the overall low number of neoplastic lesions.

Finally, these findings are supported by a recent systematic review that demonstrated a superiority of CE over WLE in dysplasia detection when compared to SD-WLE only with no direct evidence of prevention of cancer-related mortality and time to interval cancer in patients who received CE[60]. As described in this paper, there have been consistent data suggesting increased dysplasia detection with CE, however data showing an impact in cancer related outcomes are still lacking. More longitudinal head to head studies comparing CE with HD-WLE are needed to compare the outcomes of surveillance techniques and to confirm whether the clinical significance of these lesions are indeed comparable.

**Future Directions**

CE appears to increase the rate of colonic dysplasia detection in IBD patients undergoing CAC surveillance. CE with targeted biopsies is now an alternative to random biopsies for CAC surveillance. However, we currently do not have sufficient data to suggest that there is a clear “real-world” benefit of CE including reduction in cancer rates or improved survival. As such, further studies are required to assess the effect on CAC outcomes, not only dysplasia detection rates. Patients are likely to seek answers from their gastroenterologist regarding the “best” way to prevent colorectal cancer. It is important that we are prepared to explain to patients how CE fits into their care.

It is likely that the future of CAC will be increasingly complex as our understanding of dysplasia in IBD and technologies available to detect and treat dysplasia evolve. Risk stratification will likely play a larger role in identifying patients most at risk for CAC who would most likely benefit from aggressive CAC surveillance, including CE.

It is imperative that more studies, particularly longitudinal studies should be done to clarify the role of CE in achieving the ultimate goal of reducing patient morbidity and mortality from CAC while also reducing unnecessary colectomies in patients with clinically insignificant lesions.

**References**

1 **Bargen JA**. Chronic ulcerative colitis associated with malignant disease. 1928. *Dis Colon Rectum* 1994; **37**: 727-730 [PMID: 8026242 DOI: 10.1007/BF02054420]

2 **Goldgraber MB**, Kirsner JB. Carcinoma of the colon in ulcerative colitis. *Cancer* 1964; **17**: 657-665 [PMID: 14159812 DOI: 10.1002/1097-0142(196405)17:53.0.CO;2-7]

3 **Crohn BB.** Sigmoidoscopic picture of chronic colitis (nonspecific). *Am J Med Sci* 1925; **170**: 220-228 [DOI: 10.1097/00000441-192508010-00006]

4 **Winawer S**, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. *Gastroenterology* 2003; **124**: 544-560 [PMID: 12557158 DOI: 10.1053/gast.2003.50044]

5 **Levin B**, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology* 2008; **134**: 1570-1595 [PMID: 18384785 DOI: 10.1053/j.gastro.2008.02.002]

6 **Annese V**, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 982-1018 [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016]

7 **American Society for Gastrointestinal Endoscopy Standards of Practice Committee.**, Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. *Gastrointest Endosc* 2015; **81**: 1101-21.e1-13 [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030]

8 **Jung M**, Kiesslich R. Chromoendoscopy and intravital staining techniques. *Baillieres Best Pract Res Clin Gastroenterol* 1999; **13**: 11-19 [PMID: 11030630 DOI: 10.1053/bega.1999.0004]

9 **Tada M**, Katoh S, Kohli Y, Kawai K. On the dye spraying method in colonofiberscopy. *Endoscopy* 1977; **8**: 70-74 [PMID: 67941 DOI: 10.1055/s-0028-1098379]

10 **Jaramillo E**, Watanabe M, Befrits R, Ponce de León E, Rubio C, Slezak P. Small, flat colorectal neoplasias in long-standing ulcerative colitis detected by high-resolution electronic video endoscopy. *Gastrointest Endosc* 1996; **44**: 15-22 [PMID: 8836711 DOI: 10.1016/S0016-5107(96)70223-7]

11 **Warren S**, Sommers SC. Pathogenesis of ulcerative colitis. *Am J Pathol* 1949; **25**: 657-679 [PMID: 18152861]

12 **Morson BC**, Pang LS. Rectal biopsy as an aid to cancer control in ulcerative colitis. *Gut* 1967; **8**: 423-434 [PMID: 6057771 DOI: 10.1136/gut.8.5.423]

13 **Riddell RH**, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol* 1983; **14**: 931-968 [PMID: 6629368 DOI: 10.1016/S0046-8177(83)80175-0]

14 **Eaden JA**, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; **48**: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]

15 **Winther KV**, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. *Clin Gastroenterol Hepatol* 2004; **2**: 1088-1095 [PMID: 15625654 DOI: 10.1016/S1542-3565(04)00543-9]

16 **Rutter MD**, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterology* 2006; **130**: 1030-1038 [PMID: 16618396 DOI: 10.1053/j.gastro.2005.12.035]

17 **Söderlund S**, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. *Gastroenterology* 2009; **136**: 1561-7; quiz 1818-9 [PMID: 19422077]

18 **Kim BJ**, Yang SK, Kim JS, Jeen YT, Choi H, Han DS, Kim HJ, Kim WH, Kim JY, Chang DK. Trends of ulcerative colitis-associated colorectal cancer in Korea: A KASID study. *J Gastroenterol Hepatol* 2009; **24**: 667-671 [PMID: 19378391 DOI: 10.1111/j.1440-1746.2008.05730.x]

19 **Jess T**, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ 3rd, Munkholm P, Sandborn WJ. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. *Gastroenterology* 2006; **130**: 1039-1046 [PMID: 16618397 DOI: 10.1053/j.gastro.2005.12.037]

20 **Jess T**, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. *Gastroenterology* 2012; **143**: 375-81.e1; quiz e13-4 [PMID: 22522090 DOI: 10.1053/j.gastro.2012.04.016]

21 **Jess T**, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol* 2012; **10**: 639-645 [PMID: 22289873 DOI: 10.1016/j.cgh.2012.01.010]

22 **Bernstein CN**, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer* 2001; **91**: 854-862 [PMID: 11241255 DOI: 10.1002/1097-0142(20010215)91:43.0.CO;2-Z]

23 **Rutter M**, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 2004; **126**: 451-459 [PMID: 14762782 DOI: 10.1053/j.gastro.2003.11.010]

24 **Munkholm P**. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. *Aliment Pharmacol Ther* 2003; **18 Suppl 2**: 1-5 [PMID: 12950413 DOI: 10.1046/j.1365-2036.18.s2.2.x]

25 **Rubin DT**, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? *Gastrointest Endosc* 2007; **65**: 998-1004 [PMID: 17451704 DOI: 10.1016/j.gie.2006.09.025]

26 **Rutter MD**, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. *Gastrointest Endosc* 2004; **60**: 334-339 [PMID: 15332019 DOI: 10.1016/S0016-5107(04)01710-9]

27 **Blonski W**, Kundu R, Lewis J, Aberra F, Osterman M, Lichtenstein GR. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? *Scand J Gastroenterol* 2008; **43**: 698-703 [PMID: 18569987 DOI: 10.1080/00365520701866150]

28 **Collins PD**, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *Cochrane Database Syst Rev* 2006; **(2)**: CD000279 [PMID: 16625534 DOI: 10.1002/14651858.CD000279.pub3]

29 **Choi PM**, Nugent FW, Schoetz DJ Jr, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. *Gastroenterology* 1993; **105**: 418-424 [PMID: 8335197 DOI: 10.1016/0016-5085(93)90715-O]

30 **Lynch DA**, Lobo AJ, Sobala GM, Dixon MF, Axon AT. Failure of colonoscopic surveillance in ulcerative colitis. *Gut* 1993; **34**: 1075-1080 [PMID: 8174957 DOI: 10.1136/gut.34.8.1075]

31 **Ananthakrishnan AN**, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2015; **13**: 322-329.e1 [PMID: 25041865 DOI: 10.1016/j.cgh.2014.07.018]

32 **Itzkowitz SH**, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. *Gastroenterology* 2004; **126**: 1634-1648 [PMID: 15168373 DOI: 10.1053/j.gastro.2004.03.025]

33 **Rubin CE**, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. *Gastroenterology* 1992; **103**: 1611-1620 [PMID: 1426881 DOI: 10.1016/0016-5085(92)91185-7]

34 **Awais D**, Siegel CA, Higgins PD. Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity. *Gut* 2009; **58**: 1498-1503 [PMID: 19651634 DOI: 10.1136/gut.2008.169714]

35 **Eaden J**, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. *Aliment Pharmacol Ther* 2000; **14**: 145-153 [PMID: 10651654 DOI: 10.1046/j.1365-2036.2000.00698.x]

36 **Eaden JA**, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. *Gastrointest Endosc* 2000; **51**: 123-128 [PMID: 10650251 DOI: 10.1016/S0016-5107(00)70405-6]

37 **Obrador A**, Ginard D, Barranco L. Review article: colorectal cancer surveillance in ulcerative colitis - what should we be doing? *Aliment Pharmacol Ther* 2006; **24** Suppl 3: 56-63 [PMID: 16961747 DOI: 10.1111/j.1365-2036.2006.03062.x]

38 **Gasia MF**, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M. Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. *Clin Gastroenterol Hepatol* 2016; **14**: 704-12.e4 [PMID: 26804384 DOI: 10.1016/j.cgh.2015.12.047]

39 **Watanabe T**, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. *Gastroenterology* 2016; **151**: 1122-1130 [PMID: 27523980 DOI: 10.1053/j.gastro.2016.08.002]

40 **Laine L**, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology* 2015; **148**: 639-651.e28 [PMID: 25702852 DOI: 10.1053/j.gastro.2015.01.031]

41 **Marion JF**, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. *Gastroenterology* 2015; **148**: 462-467 [PMID: 25702851 DOI: 10.1053/j.gastro.2015.01.029]

42 **Rutter MD**, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. *Gut* 2004; **53**: 256-260 [PMID: 14724160 DOI: 10.1136/gut.2003.016386]

43 **Kiesslich R**, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. *Gastroenterology* 2003; **124**: 880-888 [PMID: 12671882 DOI: 10.1053/gast.2003.50146]

44 **Subramanian V**, Mannath J, Ragunath K, Hawkey CJ. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. *Aliment Pharmacol Ther* 2011; **33**: 304-312 [PMID: 21128987 DOI: 10.1111/j.1365-2036.2010.04525.x]

45 **Farraye FA**, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 2010; **138**: 746-774, 774.e1-4; quiz e12-3 [PMID: 20141809 DOI: 10.1053/j.gastro.2009.12.035]

46 **Cairns SR**, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut* 2010; **59**: 666-689 [PMID: 20427401 DOI: 10.1136/gut.2009.179804]

47 **Mooiweer E**, van der Meulen-de Jong AE, Ponsioen CY, Fidder HH, Siersema PD, Dekker E, Oldenburg B. Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study. *Am J Gastroenterol* 2015; **110**: 1014-1021 [PMID: 25823770 DOI: 10.1038/ajg.2015.63]

48 **Ignjatovic A**, East JE, Subramanian V, Suzuki N, Guenther T, Palmer N, Bassett P, Ragunath K, Saunders BP. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. *Am J Gastroenterol* 2012; **107**: 885-890 [PMID: 22613903 DOI: 10.1038/ajg.2012.67]

49 **Carballal S**, Maisterra S, López-Serrano A, Gimeno-García AZ, Vera MI, Marín-Garbriel JC, Díaz-Tasende J, Márquez L, Álvarez MA, Hernández L, De Castro L, Gordillo J, Puig I, Vega P, Bustamante-Balén M, Acevedo J, Peñas B, López-Cerón M, Ricart E, Cuatrecasas M, Jimeno M, Pellisé M; EndoCAR group of the Spanish Gastroenterological Association and Spanish Digestive Endoscopy Society. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. *Gut* 2016; Epub ahead of print [PMID: 27612488 DOI: 10.1136/gutjnl-2016-312332]

50 **Marion JF**, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L; Chromoendoscopy Study Group at Mount Sinai School of Medicine. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. *Am J Gastroenterol* 2008; **103**: 2342-2349 [PMID: 18844620 DOI: 10.1111/j.1572-0241.2008.01934.x]

51 **Matsumoto T**, Nakamura S, Jo Y, Yao T, Iida M. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. *Am J Gastroenterol* 2003; **98**: 1827-1833 [PMID: 12907339 DOI: 10.1111/j.1572-0241.2003.07580.x]

52 **Hurlstone DP**, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. *Endoscopy* 2005; **37**: 1186-1192 [PMID: 16329015 DOI: 10.1055/s-2005-921032]

53 **Kiesslich R**, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M, Vieth M, Nafe B, Galle PR, Neurath MF. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. *Gastroenterology* 2007; **132**: 874-882 [PMID: 17383417 DOI: 10.1053/j.gastro.2007.01.048]

54 **ASGE Technology Committee.** Wong Kee Song LM, Adler DG, Chand B, Conway JD, Croffie JM, Disario JA, Mishkin DS, Shah RJ, Somogyi L, Tierney WM, Petersen BT. Chromoendoscopy. *Gastrointest Endosc* 2007; **66**: 639-649 [PMID: 17643437 DOI: 10.1016/j.gie.2007.05.029]

55 **Konijeti GG**, Shrime MG, Ananthakrishnan AN, Chan AT. Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. *Gastrointest Endosc* 2014; **79**: 455-465 [PMID: 24262637 DOI: 10.1016/j.gie.2013.10.026]

56 **Leong RW**, Butcher RO, Picco MF. Implementation of image-enhanced endoscopy into solo and group practices for dysplasia detection in Crohn's disease and ulcerative colitis. *Gastrointest Endosc Clin N Am* 2014; **24**: 419-425 [PMID: 24975532 DOI: 10.1016/j.giec.2014.04.001]

57 **van den Broek FJ**, Stokkers PC, Reitsma JB, Boltjes RP, Ponsioen CY, Fockens P, Dekker E. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. *Am J Gastroenterol* 2014; **109**: 715-722 [PMID: 21427710 DOI: 10.1038/ajg.2011.93]

58 **Marion JF**, Waye JD, Israel Y, Present DH, Suprun M, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Abreu MT, Ullman TA, McBride RB, Aisenberg J, Mayer L; Chromoendoscopy Study Group at Mount Sinai School of Medicine. Chromoendoscopy Is More Effective Than Standard Colonoscopy in Detecting Dysplasia During Long-term Surveillance of Patients With Colitis. *Clin Gastroenterol Hepatol* 2016; **14**: 713-719 [PMID: 26656297 DOI: 10.1016/j.cgh.2015.11.011]

59 **Ten Hove JR**, Mooiweer E, van der Meulen de Jong AE, Dekker E, Ponsioen CY, Siersema PD, Oldenburg B. Clinical implications of low grade dysplasia found during inflammatory bowel disease surveillance: a retrospective study comparing chromoendoscopy and white-light endoscopy. *Endoscopy* 2017; **49**: 161-168 [PMID: 27951611 DOI: 10.1055/s-0042-119394]

60 **Iannone A**, Ruospo M, Wong G, Principi M, Barone M, Strippoli GF, Di Leo A. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials. *Clin Gastroenterol Hepatol* 2016; Epub ahead of print [PMID: 27890853 DOI: 10.1016/j.cgh.2016.11.021]

**P-Reviewer:** Kim JS, Shakhnovich V, Tontini GE **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Colorectal cancer surveillance guidelines for inflammatory bowel disease patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Guideline (year of publication)** | **Timing of initiating surveillance** | **Surveillance interval** | **Biopsy protocol** |
| AGA (2003)[4] | After 8 yr of disease (pancolitis)  After 15 yr of disease  (left-sided colitis) | 1-2 yr | Random biopsy |
| BSG (2010)[46] | 10 yr after onset of colitic symptoms | 5 yr (lower risk)1  2-3 yr (intermediate risk)  1 yr (higher risk) | Targeted biopsy with CE (preferred) otherwise random biopsy |
| ECCO (2013)[6] | 8 yr after onset of colitic symptoms | 5 yr (lower risk)2  2-3 yr (intermediate risk)  1 yr (higher risk) | Targeted biopsy with CE (preferred), random biopsies if CE expertise unavailable |
| ASGE (2015)[7] | 8 yr after symptom onset | 1-3 yr (1 yr if any risk factor)3 | Targeted biopsy with CE recommended with SD-WLE (preferred with HD-WLE as well); random biopsies with targeted biopsies of suspicious lesions is alternative |

1Higher risk group: dysplasia in the past 5 years declining surgery, PSC/liver transplantation for PSC, family history of CRC in a first degree relative < 50 yr, or extensive colitis with moderate/severe active endoscopic/histological inflammation; Intermediate risk group: post-inflammatory polyps, family history of CRC in a first degree relative > 50 years, extensive colitis with mild active endoscopic/histologic inflammation; Lower risk group: left sided colitis, Crohn’s colitis with less than 50% of the colonic mucosal surface affected by the disease, or extensive colitis with no active endoscopic/histologic inflammation. 2Higher risk group: stricture or dysplasia in the past 5 years, PSC, extensive colitis with severe active inflammation, or family history of CRC in a first degree relative < 50 yr; Intermediate risk group: extensive colitis with mild or moderate active inflammation post-inflammatory polyps, or family history of CRC in a first degree relative > 50 yr; Lower risk group: patients with neither intermediate nor higher risk features. 3Risk factors: active inflammation, anatomic abnormality (stricture or multiple pseudopolyps), history of dysplasia, family history of CRC in a first degree relative, PSC. AGA: American Gastroenterological Association; BSG: British Society of Gastroenterology; ECCO: European Crohn’s and Colitis Organisation; ASGE: American Society of Gastrointestinal Endoscopy; PSC: primary sclerosing cholangitis; CRC: colorectal cancer; CE: chromoendoscopy; SD-WLE: standard definition white light endoscopy; HD-WLE: high definition white light endoscopy.